Physician profile
Patrick A Costello
NPI 1346245156
$6,070.57
in general payments reported to CMS, 2019-2025
32 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $838 · 2021: $956 · 2022: $996 · 2023: $437 · 2024: $799 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,377.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,901.07 | 2019-2025 | Rocklatan, Clareon, Eysuvis |
| Sight Sciences, INC. | $471.92 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $415.75 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Beaver-Visitec International, INC. | $366.01 | 2022-2023 | |
| Abbvie INC. | $321.31 | 2024-2025 | |
| Glaukos Corporation | $247.86 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $228.46 | 2019-2025 | Cequa |
| Allergan, INC. | $220.28 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $181.12 | 2019-2025 | Tecnis Iol, Tecnis Simplicity |
| Oyster Point Pharma, INC. | $173.05 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $171.87 | 2019-2021 | |
| Biotissue Holdings INC. | $167.77 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $134.56 | 2021-2023 | Acthar |
| Amgen INC. | $126.68 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $111.58 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $97.21 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $95.49 | 2024-2025 | Xdemvy |
| Carl Zeiss Meditec, INC. | $75.52 | 2019 | |
| Omeros Corporation | $71.65 | 2019-2021 | |
| Ocular Therapeutix, INC. | $69.87 | 2019-2025 | Dextenza |
| Merz Pharmaceuticals, LLC | $66.95 | 2024-2025 | Xeomin |
| Takeda Pharmaceuticals U.S.A., INC. | $57.42 | 2020-2022 | |
| Ivantis, INC | $54.90 | 2020-2021 | |
| Harrow Eye, LLC | $50.87 | 2024-2025 | Iheezo |
| Horizon Therapeutics Plc | $43.06 | 2023 | Tepezza |
| Dompe US, INC. | $34.72 | 2021-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $32.64 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $25.62 | 2025 | Syfovre |
| Rayner Intraocular Lenses Limited | $21.20 | 2025 | Omidria |
| Eyepoint US, INC. | $13.71 | 2019 | |
| Medtronic, INC. | $11.26 | 2021 | |
| New World Medical,INC. | $9.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Costello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.